|
|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2026
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/34425
| Title: | TUBERCULOSIS ACTIVATION UNDER BIOLOGICAL TREATMENT WITH ANTI - TNFA IN ULCERATIVE COLITIS |
| Authors: | Cuşnir, Magdalena |
| Keywords: | ulcerative colitis;tuberculosis;adalimumab;antiTNF |
| Issue Date: | 2026 |
| Publisher: | Centrul Editorial-Poligrafic Medicina |
| Citation: | Cuşnir, Magdalena. TUBERCULOSIS ACTIVATION UNDER BIOLOGICAL TREATMENT WITH ANTI - TNFA IN ULCERATIVE COLITIS. In: MedEspera 2026, p. 610. ISBN 978-9975-82-486-6. |
| Abstract: | Introduction. Tuberculosis activation is a major complication of anti-TNF biological therapy in patients with inflammatory bowel disease. Endemic regions studies estimate a risk of 8-19% for the development of tuberculosis in patients undergoing anti-TNF treatment. Adalimumab interferes with the integrity of the tuberculous granuloma, facilitating the reactivation of latent M.tuberculosis through “reverse signaling” of membrane TNF(tmTNF) and by increasing TGF-pi, favoring bacillary replication. TNF-blockers also reduce the inflammatory immune response. Case presentation. 27-year-old patient, diagnosed in October 2023 with ulcerative colitis with pan-colonic involvement, characterized by frequent relapses and severe activity, complicated by pathological stenosis in the distal descending colon. In November 2023, anti-TNF therapy with adalimumab was initiated after a negative screening for tuberculosis. After 9 months of treatment, the patient discontinued therapy due to the appearance of cough, chest pain and fever, and was subsequently diagnosed with tuberculosis with multiple localizations: infiltrative pulmonary TBC (GeneXpert MTB/RIF positive, RIF sensitive), bronchial TBC and paratracheal adenopathy confirmed histologically. Antituberculosis treatment was instituted according to the RIPE scheme for 9 months, with favorable evolution and declaration of cure. Two months after completing antituberculosis therapy, the digestive symptoms worsened, with up to 10 diarrheal stools/day, with mucus and blood, and abdominal pain in the left iliac fossa, the patient being admitted to the Gastroenterology unit of the Republican Clinical Hospital. Based on anamnesis and investigations performed: colonoscopy and histological examination, coprological examination and tumor markers (CEA, AFP, CA 19-9, CA 72-4), immunosuppressive therapy with azathioprine 50mg twice daily was initiated for a period of 2 months, associated with prednisolone 20mg/day for 2 weeks, with progressive dose reduction. Subsequent reassessment of the therapeutic response is planned. Discussions. This is the case of a young patient with severe ulcerative colitis in whom adalimumab therapy led to reactivation of latent tuberculosis, emphasizing that the infectious risk is not eliminated after an initial negative screening. This highlights the need for continuous clinical and paraclinical monitoring throughout anti-TNF biological treatment, not only in the pre-therapeutic phase. Conclusions. Anti-TNF therapy in patients with severe ulcerative colitis carries a significant risk of reactivation of latent tuberculosis, requiring rigorous screening before initiation and monitoring during treatment. The sequential therapeutic approach: complete antituberculosis treatment, followed by transition to azathioprine, allowed control of inflammatory disease activity without tuberculosis activation risk. |
| metadata.dc.relation.ispartof: | MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026 |
| URI: | https://medespera.md/documents/abstract-book-4.pdf https://repository.usmf.md/handle/20.500.12710/34425 |
| ISBN: | 978-9975-82-486-6 |
| Appears in Collections: | MedEspera 2026
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|